CORONABSECorona Remedies LtdHighPositive
Announced Thu, 28 May · 15:34 IST

Press Release - Receipt of EU-GMP Certification

Regulatory Product ApprovalBusiness Updates View source PDF

CORONA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
+0.5%1-day move
₹1678.40
prior close
₹1700.00
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-0.1-0.2-0.3-0.3+0.5+0.8+1.7+1.3+2.6+5.7+11.0+17.1
Up moveDown movePending
AI summary

Corona Remedies has received EU-GMP Compliance Certification for its Hormone manufacturing facility and renewed EU-GMP approval for its Oral Solid Dosage facility in Bhayla, Ahmedabad. The certification followed an EUDRA GMP inspection conducted in April 2026. This accreditation enables the company to supply products to regulated and semi-regulated markets including the European Union, moving beyond its current India-focused operations. The company stated its goal to take its Hormone portfolio to global markets, with the executive director emphasising the 'One World. One Quality' philosophy. No specific export orders or financial figures were disclosed.

Likely market impact

This certification enhances Corona Remedies' ability to export to high-value regulated markets like the EU, potentially opening new revenue streams in hard currencies. However, no immediate orders or financial guidance were provided, so the stock impact may be limited to sentiment around future growth potential.